Columnist Anna Jeter was recently reminded that she's still absorbing lessons from her chronic illness after 25 years of ...

Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, ...

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I'm dealing with the effects of it ...

Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim ...

Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...

Winrevair was approved to treat pulmonary arterial hypertension (PAH), a progressive disorder caused by a constriction of ...

Merck , known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary ...

Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, ...

The 2025 GOLD COPD report has a new emphasis on CV disease and PH in COPD and major updates on new drugs, climate change, and ...